Ganga Pharmaceuticals (539680) H2 20/21 earnings summary

Executive summary

• FY2020-21 operating revenue fell to ₹23.74m from ₹30.79m; profit after tax declined to ₹0.20m from ₹1.89m amid COVID-related disruption.

• Ayurvedic medicines manufacturing and trading remained the core business; plans focused on product development, distribution expansion and domestic Ayurveda demand.

Financial highlights

• Revenue from operations was ₹23.74m vs ₹30.79m; total revenue was ₹26.29m vs ₹32.44m, with other income rising to ₹2.54m from ₹1.65m.

• Profit before tax fell to ₹0.37m from ₹2.55m; profit after tax was ₹0.20m vs ₹1.89m.

• Material costs rose to ₹14.21m from ₹11.67m; other expenses declined to ₹6.79m from ₹9.79m.

Outlook and guidance

• Long-term priorities: scale authentic Ayurveda, develop products for unmet medical needs, improve customer relationships, expand domestic distribution and commercialize patented products targeting diabetes, inflammation and obesity.

• Human clinical trials were conducted for some new formulations; plans also emphasized new product distribution networks and product innovation.